Recent evidence suggests that decreased plasma fibrinolysis is a risk factor for venous thromboembolism, and that cell surface tPA receptor, especially AnxA2 is involved in this hypofibrinolysis [104,105]. This evidence concerns the gene ANXA2 and venous thromboembolism.